Pharma Packaging and Labelling Compliance Conference

Fleming Europe23 - 25 March 2011, Barcelona, Spain.
As pharmaceutical and patient landscape is constantly developing worldwide, excellence in strategic packaging and labelling has become essential to regulatory compliance, patient adherence, safety and sustainability.

Fleming Europe has selected from across the globe the highest-level pharmapack specialists, who will share their many market-specific local interpretations, which will influence pharmaceutical packaging and labelling structurally in 2011.

Listen to them speaking about the latest regulations coming into effect in the next months (including PharmaBraille and 2D Datamatrix Marking System). Discover various ways of patient adherence and the business models of in-house vs. outsourced artwork management. Be part of interactive roundtables focusing on the most advanced technologies of pharmapack traceability.…and listen to real-life case studies of anti-counterfeiting, parallel trade and packaging sustanability.

This 3-Day-Event includes a target audience focused post-conference workshop in 2 streams, which will bring together innovative, responsible and cost-effective methods of pharmaceutical and medical packaging, addressing key labelling issues as well as creating partnerships between industry leaders.

Key speakers:

  • Executive Director, Healthcare Compliance Packaging Council (HCPC), Austria
  • Director, Global Regulatory Affairs Strategic Policy & Support, Johnson&Johnson, UK
  • Secretary General, Child-Safe Packaging Group, UK
  • Head of Packaging Strategy, Global Pharma Operations, Novartis, Switzerland
  • Head of Patient Information Quality, MHRA, UK
  • Director of Materials and Packaging Quality System, Eli Lilly, USA
  • Director of Healthcare Traceability, GS1 Global, UK
  • Head of Pharmacy Trade Sector, Roche Diagnostics, Germany

Key topics:

  • Packaging & Labelling Regulatory Updates
  • Patient Adherence
  • Excellence in Artwork Management: In-house vs. Outsourced
  • Traceability to Combat Non-compliance
  • Packaging suitable for the Blind – Braille-Guidelines according to the European standards implemented from October 2010
  • Innovative 2D Datamatrix System for Pharma Traceability
  • Anti-Counterfeiting using Advanced Technology
  • Parallel Traders Perspectives
  • Sustainable Packaging Innovations
  • Child-safe vs. Senior friendly Packaging – Balancing Patients’ Needs
  • Information based Packaging Redesign

Who should attend:
VPs, Directors, Heads and Managers of Packaging, Labelling, Supply Chain and Logistics, Regulatory Affairs and Compliance, Quality Assurance, Product Information, Product Development, Operations, Quality Control and Assurance, Licensing, Marketing and Sales, Patient Compliance, Purchase / Facilities, Manufacturing Technology, International Labelling Liaison, Packaging Designer, Global Labelling.

For further information and registration, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/pharma-packaging-and-labelling-compliance-conference

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...